Nanomedicine as A Promising Approach For Diagnosis, Treatment and Prophylaxis Against COVID-19

References

• Coleman CM , LiuYV, MuHet al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine32(26), 3169–3174 (2014).
   PubMed Web of Science ®Google Scholar
• Coleman CM , FriemanMB. Coronaviruses: important emerging human pathogens. J. Virol.88(10), 5209–5212 (2014).
   PubMed Web of Science ®Google Scholar
• STAT Medicine . Synthetic biologists think they can develop a better coronavirus vaccine than nature could. http://www.scientificamerican.com/article/synthetic-biologists-think-they-can-develop-a-better-coronavirus-vaccine-than-nature-could/
   Google Scholar
• World Health Organisation . WHO announces COVID-19 outbreak a pandemic. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic
   Google Scholar
• World Health Organisation . Coronavirus disease (COVID-19) situation report – 168. http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200706-covid-19-sitrep-168.pdf?sfvrsn=7fed5c0b_2
   Google Scholar
• Sekimukai H , Iwata-YoshikawaN, FukushiSet al. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs. Microbiol. Immunol.64(1), 33–51 (2019).
   PubMed Web of Science ®Google Scholar
• Coleman CM , VenkataramanT, LiuYVet al. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine35(12), 1586–1589 (2017).
   PubMed Web of Science ®Google Scholar
• Layqah LA , EissaS. An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. Microchimica Acta186(4), 224 (2019).
   PubMed Web of Science ®Google Scholar
• Wang M , CaoR, ZhangLet al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res.30(3), 269–271 (2020).
   PubMed Web of Science ®Google Scholar
• Candanosa RM . Here’s how nanoparticles could help us get closer to a treatment for COVID-19. https://news.northeastern.edu/2020/03/04/heres-how-nanoparticles-could-help-us-get-closer-to-a-treatment-for-covid-19/
   Google Scholar
• Ahn DG , ShinHJ, KimMHet al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J. Microbiol. Biotechnol.30(3), 313–324 (2020).
   PubMed Web of Science ®Google Scholar
• Łoczechin A , SéronK, BarrasAet al. Functional carbon quantum dots as medical countermeasures to human coronavirus. ACS Appl. Mater. Interfaces11(46), 42964–42974 (2019).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention Public Health Image Library . Image 23354. https://phil.cdc.gov/Details.aspx?pid=23354
   Google Scholar
• Guo YR , CaoQD, HongZSet al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil. Med. Res.7(1), 11 (2020).
   PubMed Web of Science ®Google Scholar
• Wu F , ZhaoS, YuBet al. A new coronavirus associated with human respiratory disease in China. Nature579(7798), 265–269 (2020).
   PubMed Web of Science ®Google Scholar
• Khailany RA , SafdarM, OzaslanM. Genomic characterization of a novel SARS-CoV-2. Gene Rep.19, 100682 (2020).
   PubMed Web of Science ®Google Scholar
• Fehr AR , PerlmanS. Coronaviruses: an overview of their replication and pathogenesis. In: Coronaviruses: Methods in Molecular Biology.MaierHJ, BickertonE, BrittonP ( Eds). Humana Press, NY, USA, 1–23 (2015).
   Google Scholar
• Bárcena M , OostergetelGT, BartelinkWet al. Cryo-electron tomography of mouse hepatitis virus: insights into the structure of the coronavirion. Proc. Natl Acad. Sci. USA106(2), 582–587 (2009).
   PubMed Web of Science ®Google Scholar
• Neuman BW , AdairBD, YoshiokaCet al. Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J. Virol.80(16), 7918–7928 (2006).
   PubMed Web of Science ®Google Scholar
• Sui J , LiW, MurakamiAet al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl Acad. Sci. USA101(8), 2536–2541 (2004).
   PubMed Web of Science ®Google Scholar
• Raj VS , MouH, SmitsSLet al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus – EMC. Nature495(7440), 251–254 (2013).
   PubMed Web of Science ®Google Scholar
• Li W , MooreMJ, VasilievaNet al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature426(6965), 450–454 (2003).
   PubMed Web of Science ®Google Scholar
• Zhou P , YangX-L, WangX-Get al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature579(7798), 270–273 (2020).
   PubMed Web of Science ®Google Scholar
• Andersen KG , RambautA, LipkinWI, HolmesEC, GarryRF. The proximal origin of SARS-CoV-2. Nat. Med.26(4), 450–452 (2020).
   PubMed Web of Science ®Google Scholar
• Statnano.com . An overview of nanotechnology patents focusing on coronaviruses. https://statnano.com/news/67513/An-Overview-of-Nanotechnology-Patents-Focusing-on-Coronaviruses
   Google Scholar
• Udugama B , KadhiresanP, KozlowskiHNet al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano14(4), 3822–3835 (2020).
   PubMed Web of Science ®Google Scholar
• Li W , ShiZ, YuMet al. Bats Are natural reservoirs of SARS-like coronaviruses. Science310(5748), 676–679 (2005).
   PubMed Web of Science ®Google Scholar
• Lau SKP , WooPCY, LiKSMet al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl Acad. Sci. USA102(39), 14040–14045 (2005).
   PubMed Web of Science ®Google Scholar
• Poon LLM , ChuDKW, ChanKHet al. Identification of a novel coronavirus in bats. J. Virol.79(4), 2001–2009 (2005).
   PubMed Web of Science ®Google Scholar
• Corman VM , ItheteNL, RichardsLRet al. Rooting the phylogenetic tree of Middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. J. Virol.88(19), 11297–11303 (2014).
   PubMed Web of Science ®Google Scholar
• van Boheemen S , de GraafM, LauberCet al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio3(6), e00473–00412 (2012).
   PubMed Web of Science ®Google Scholar
• Zaki AM , van BoheemenS, BestebroerTM, OsterhausADME, FouchierRAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med.367(19), 1814–1820 (2012).
   PubMed Web of Science ®Google Scholar
• Lu R , ZhaoX, LiJet al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet395(10224), 565–574 (2020).
   PubMed Web of Science ®Google Scholar
• Guo Y-R , CaoQ-D, HongZ-Set al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil. Med. Res.7(1), 1–10 (2020).
   PubMed Web of Science ®Google Scholar
• Zhou P , YangXL, WangXGet al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature579(7798), 270–273 (2020).
   PubMed Web of Science ®Google Scholar
• Amanat F , KrammerF. SARS-CoV-2 vaccines: status report. Immunity52(4), 583–589 (2020).
   PubMed Web of Science ®Google Scholar
• Ai T , YangZ, HouHet al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology doi: 10.1148/radiol.2020200642 (2020) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K , WardSA, Kalantar-ZadehK, El-OmarEM. Considering the effects of microbiome and diet on SARS-CoV-2 infection: nanotechnology roles. ACS Nano14(5), 5179–5182 (2020).
   PubMed Web of Science ®Google Scholar
• Zuo T , ZhangF, LuiGCYet al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology doi: 10.1053/j.gastro.2020.05.048 (2020) ( Epub ahead of print).
   Google Scholar
• Petrosillo N , ViceconteG, ErgonulO, IppolitoG, PetersenE. COVID-19, SARS and MERS: are they closely related?Clin. Microbiol. Infect.26(6), 729–734 (2020).
   PubMed Web of Science ®Google Scholar
• Liu J , LiaoX, QianSet al. Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, 2020. Emerg. Infect. Dis.26(6), 1320–1323 (2020).
   PubMed Web of Science ®Google Scholar
• Chan JFW , YuanS, KokKHet al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet395(10223), 514–523 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang Y , ChenC, ZhuSet al. Isolation of 2019-nCoV from a stool specimen of a laboratory-confirmed case of the coronavirus disease 2019 (COVID-19). CCDC Weekly2(8), 123–124 (2020).
   PubMedGoogle Scholar
• Xiao F , TangM, ZhengX, LiuY, LiX, ShanH. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology158(6), 1831–1833 (2020).
   PubMed Web of Science ®Google Scholar
• Holmes KV , EnjuanesL. The SARS coronavirus: a postgenomic era. Science300(5624), 1377–1378 (2003).
   PubMed Web of Science ®Google Scholar
• Menachery VD , GralinskiLE, MitchellHDet al. Combination attenuation offers strategy for live attenuated coronavirus vaccines. J. Virol.92(17), e00710–00718 (2018).
   PubMed Web of Science ®Google Scholar
• Graham RL , DemingDJ, DemingME, YountBL, BaricRS. Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform. Commun. Biol1(1), 1–10 (2018).
   PubMedGoogle Scholar
• Kruse RL . Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res.9, 72–72 (2020).
   PubMedGoogle Scholar
• Spruth M , KistnerO, Savidis-DachoHet al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine24(5), 652–661 (2006).
   PubMed Web of Science ®Google Scholar
• Gao Q , BaoL, MaoHet al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science369(6499), 77–81 (2020).
   PubMed Web of Science ®Google Scholar
• Yang ZY , KongWP, HuangYet al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature428(6982), 561–564 (2004).
   PubMed Web of Science ®Google Scholar
• Sardesai NY , WeinerDB. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol.23(3), 421–429 (2011).
   PubMed Web of Science ®Google Scholar
• Kim TW , LeeJH, HungC-Fet al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J. Virol.78(9), 4638–4645 (2004).
   PubMed Web of Science ®Google Scholar
• Donnelly JJ , UlmerJB, ShiverJW, LiuMA. DNA vaccines. Annu. Rev. Immunol.15(1), 617–648 (1997).
   PubMedGoogle Scholar
• Sin JI , WeinerDB. Improving DNA vaccines targeting viral infection. Intervirology43(4–6), 233–246 (2000).
   PubMed Web of Science ®Google Scholar
• Wang SF , TsengSP, YenCHet al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem. Biophys. Res. Commun.451(2), 208–214 (2014).
   PubMed Web of Science ®Google Scholar
• Wan Y , ShangJ, SunSet al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J. Virol.94(5), e02015–02019 (2020).
   PubMed Web of Science ®Google Scholar
• Tirado SMC , YoonK-J. Antibody-dependent enhancement of virus infection and disease. Viral Immunol.16(1), 69–86 (2003).
   PubMed Web of Science ®Google Scholar
• Seo SH , WangL, SmithR, CollissonEW. The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection. J. Virol.71(10), 7889–7894 (1997).
   PubMed Web of Science ®Google Scholar
• Inovio . Inovio accelerates timeline for COVID-19 DNA vaccine INO-4800. http://ir.inovio.com/news-releases/news-releases-details/2020/Inovio-Accelerates-Timeline-for-COVID-19-DNA-Vaccine-INO-4800/default.aspx
   Google Scholar
• Smith TRF , PatelA, RamosSet al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun.11(1), 2601 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang J , ZengH, GuJ, LiH, ZhengL, ZouQ. Progress and prospects on vaccine development against SARS-CoV-2. Vaccines8(2), E153 (2020).
   Web of Science ®Google Scholar
• Zhu FC , LiYH, GuanXHet al. Safety, tolerability, and immunogenicity of a recombinant adenovirus Type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet395(10240), 1845–1854 (2020).
   PubMed Web of Science ®Google Scholar
• PBR Staff Writer . Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial. https://www.pharmaceutical-business-review.com/news/moderna-mrna-1273-coronavirus-trial/.
   Google Scholar
• Pharmaceutical Business Review . Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial. http://www.pharmaceutical-business-review.com/news/moderna-mrna-1273-coronavirus-trial/
   Google Scholar
• Wang F , KreamRM, StefanoGB. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med. Sci. Monit.26, e924700-1–e924700-8 (2020).
   Web of Science ®Google Scholar
• Genetic Engineering & Biotechnology News . Moderna. http://www.genengnews.com/covid-19-candidates/moderna/
   Google Scholar
• Graham RL , DonaldsonEF, BaricRS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol.11, 836–848 (2013).
   PubMed Web of Science ®Google Scholar
• Okba NMA , RajVS, HaagmansBL. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. Curr. Opin. Virol.23, 49–58 (2017).
   PubMed Web of Science ®Google Scholar
• Fukushi S , FukumaA, KurosuTet al. Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA. J. Virol. Methods251, 22–29 (2018).
   PubMed Web of Science ®Google Scholar
• Fukuma A , TaniH, TaniguchiS, ShimojimaM, SaijoM, FukushiS. Inability of rat DPP4 to allow MERS-CoV infection revealed by using a VSV pseudotype bearing truncated MERS-CoV spike protein. Arch. Virol.160(9), 2293–2300 (2015).
   PubMed Web of Science ®Google Scholar
• Adney DR , WangL, van DoremalenNet al. Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses11(3), 212 (2019).
   PubMed Web of Science ®Google Scholar
• Wang Y , TaiW, YangJet al. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum. Vaccine Immunother.13(7), 1615–1624 (2017).
   PubMed Web of Science ®Google Scholar
• Zhu X , LiuQ, DuL, LuL, JiangS. Receptor-binding domain as a target for developing SARS vaccines. J. Thorac. Dis.5, S142–S148 (2013).
   PubMed Web of Science ®Google Scholar
• Lan J , YaoY, DengYet al. Recombinant receptor binding domain protein induces partial protective immunity in Rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine2(10), 1438–1446 (2015).
   PubMed Web of Science ®Google Scholar
• Chen Y , LuS, JiaHet al. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerg. Microb. Infect.6(1), 1–7 (2017).
   Google Scholar
• Jiaming L , YanfengY, YaoDet al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine35(1), 10–18 (2017).
   PubMed Web of Science ®Google Scholar
• Du L , HeY, ZhouY, LiuS, ZhengBJ, JiangS. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat. Rev. Microbiol.7(3), 226–236 (2009).
   PubMed Web of Science ®Google Scholar
• Zakhartchouk AN , SharonC, SatkunarajahMet al. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine25(1), 136–143 (2007).
   PubMed Web of Science ®Google Scholar
• Kim E , ErdosG, HuangSet al. Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development. EBioMedicine doi: 10.1016/j.ebiom.2020.102743 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Dynavax . Dynavax and Clover Biopharmaceuticals announce research collaboration to evaluate coronavirus (COVID-19) vaccine candidate with CpG 1018 adjuvant. http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-clover-biopharmaceuticals-announce-research
   Google Scholar
• Takashima Y , OsakiM, IshimaruY, YamaguchiH, HaradaA. Artificial molecular clamp: a novel device for synthetic polymerases. Angew. Chem. Int. Ed.50(33), 7524–7528 (2011).
   PubMed Web of Science ®Google Scholar
• Ahmed SF , QuadeerAA, MckayMR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses12(3), 254 (2020).
   PubMed Web of Science ®Google Scholar
• Azmi F , FuaadAhmad, HadiAl Abdullah, SkwarczynskiM, TothI. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum. Vaccine Immunother.10(3), 778–796 (2014).
   PubMed Web of Science ®Google Scholar
• Buchholz UJ , BukreyevA, YangLet al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl Acad. Sci. USA101(26), 9804–9809 (2004).
   PubMed Web of Science ®Google Scholar
• Neuman BW , KissG, KundingAHet al. A structural analysis of M protein in coronavirus assembly and morphology. J. Struct. Biol.174(1), 11–22 (2011).
   PubMed Web of Science ®Google Scholar
• Liu J , SunY, QiJet al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J. Infect. Dis.202(8), 1171–1180 (2010).
   PubMed Web of Science ®Google Scholar
• Hofmann H , HattermannK, MarziAet al. S Protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J. Virol.78(12), 6134–6142 (2004).
   PubMed Web of Science ®Google Scholar
• Sui J , LiW, MurakamiAet al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl Acad. Sci. USA101(8), 2536–2541 (2004).
   PubMed Web of Science ®Google Scholar
• Jimenez-Guardeno JM , Regla-NavaJA, Nieto-TorresJLet al. Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine. PLoS Pathog.11(10), e1005215 (2015).
   PubMed Web of Science ®Google Scholar
• Holshue ML , DeboltC, LindquistSet al. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med.382(10), 929–936 (2020).
   PubMed Web of Science ®Google Scholar
• Reina J . Remdesivir, the antiviral hope against SARS-CoV-2. Rev. Esp. Quimioter.33(3), 176–179 (2020).
   PubMed Web of Science ®Google Scholar
• Sheahan TP , SimsAC, LeistSRet al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun.11, 222 (2020).
   PubMed Web of Science ®Google Scholar
• Cascella M , RajnikM, CuomoA, DulebohnSC, DiNapoli R. Features, evaluation and treatment coronavirus (COVID-19). In: StatPearls.StatPearls Publishing, FL, USA (2020).
   Google Scholar
• Beigel JH , TomashekKM, DoddLEet al. Remdesivir for the treatment of COVID-19 – preliminary report. N. Engl. J. Med. doi: 10.1056/NEJMoa2007764 (2020) ( Epub ahead of print).
   PubMedGoogle Scholar
• Zumla A , ChanJFW, AzharEI, HuiDSC, YuenK-Y. Coronaviruses – drug discovery and therapeutic options. Nat. Rev. Drug Discov.15(5), 327–347 (2016).
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA , MomattinH, DibJ, MemishZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis20, 42–46 (2014).
   PubMed Web of Science ®Google Scholar
• Wu CY , JanJT, MaSHet al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl Acad. Sci. USA101(27), 10012 (2004).
   PubMed Web of Science ®Google Scholar
• Chu CM , ChengVCC, HungIFNet al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax59(3), 252–256 (2004).
   PubMed Web of Science ®Google Scholar
• Cao B , WangY, WenDet al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med.382(19), 1787–1799 (2020).
   PubMed Web of Science ®Google Scholar
• Hu TY , FriemanM, WolframJ. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat. Nanotechnol.15(4), 247–249 (2020).
   PubMed Web of Science ®Google Scholar
• Gao J , TianZ, YangX. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trend.14(1), 72–73 (2020).
   PubMed Web of Science ®Google Scholar
• Colson P , RolainJM, RaoultD. Chloroquine for the 2019 novel coronavirus. Int. J. Antimicrob. Agents55, 105923 (2020).
   PubMed Web of Science ®Google Scholar
• Savarino A , DiTrani L, DonatelliI, CaudaR, CassoneA. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis.6(2), 67–69 (2006).
   PubMed Web of Science ®Google Scholar
• Yan Y , ZouZ, SunYet al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res.23(2), 300–302 (2013).
   PubMed Web of Science ®Google Scholar
• Vincent MJ , BergeronE, BenjannetSet al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J.2(1), 69 (2005).
   PubMed Web of Science ®Google Scholar
• Rolain JM , ColsonP, RaoultD. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int. J. Antimicrob. Agents30(4), 297–308 (2007).
   PubMed Web of Science ®Google Scholar
• Karakus U , PohlMO, StertzS. Breaking the convention: sialoglycan variants, coreceptors, and alternative receptors for influenza A virus entry. J. Virol.94(4), e01357–01319 (2020).
   PubMed Web of Science ®Google Scholar
• Xu X , ChenP, WangJet al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci.63(3), 457–460 (2020).
   PubMed Web of Science ®Google Scholar
• Atluri S , ManchikantiL, HirschJA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Phys.23, E71–E83 (2020).
   PubMed Web of Science ®Google Scholar
• Janowitz T , GablenzE, PattinsonDet al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut doi: 10.1136/gutjnl-2020-321852 (2020) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Freedberg DE , ConigliaroJ, WangTCet al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology doi: 10.1053/j.gastro.2020.05.053 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Abd Ellah NH , TawfeekHM, JohnJ, HettaHF. Nanomedicine as a future therapeutic approach for Hepatitis C virus. Nanomedicine (Lond.)14(11), 1471–1491 (2019).
   PubMed Web of Science ®Google Scholar
• Lu L , SunRW, ChenR, HuiCKet al. Silver nanoparticles inhibit hepatitis B virus replication. Antiviral Ther.13(2), 253–262 (2008).
   PubMed Web of Science ®Google Scholar
• Sun RWY , ChenR, ChungNPY, HoCM, LinCLS, CheCM. Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem. Commun.40, 5059–5061 (2005).
   PubMed Web of Science ®Google Scholar
• Lara HH , Ixtepan-TurrentL, Garza-TreviñoEN, Rodriguez-PadillaC. PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J. Nanobiotechnol.8, 15–15 (2010).
   PubMedGoogle Scholar
• Sun L , SinghAK, VigK, PillaiSR, SinghSR. Silver nanoparticles inhibit replication of respiratory syncytial virus. J. Biomed. Nanotechnol.4(2), 149–158 (2008).
   Web of Science ®Google Scholar
• Papp I , SiebenC, LudwigKet al. Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles. Small6(24), 2900–2906 (2010).
   PubMed Web of Science ®Google Scholar
• Abd Ellah NH , AbouelmagdSA. Surface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges. Exp. Opin. Drug Deliv.14(2), 201–214 (2017).
   PubMed Web of Science ®Google Scholar
• Ahmad S , ZamryAA, TanHTT, WongKK, LimJ, MohamudR. Targeting dendritic cells through gold nanoparticles: a review on the cellular uptake and subsequent immunological properties. Mol. Immunol.91, 123–133 (2017).
   PubMed Web of Science ®Google Scholar
• Zhao L , SethA, WibowoNet al. Nanoparticle vaccines. Vaccine32(3), 327–337 (2014).
   PubMed Web of Science ®Google Scholar
• Pati R , ShevtsovM, SonawaneA. Nanoparticle vaccines against infectious diseases. Front. Immunol.9(2224), 2224 (2018).
   PubMedGoogle Scholar
• Mubarak A , AlturaikiW, HemidaMG. Middle East respiratory syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J. Immunol. Res.2019, 1–11 (2019).
   Web of Science ®Google Scholar
• Charlton Hume HK , VidigalJ, CarrondoMJT, MiddelbergAPJ, RoldãoA, LuaLHL. Synthetic biology for bioengineering virus-like particle vaccines. Biotechnol. Bioeng.116(4), 919–935 (2019).
   PubMed Web of Science ®Google Scholar
• Rohovie MJ , NagasawaM, SwartzJR. Virus-like particles: next-generation nanoparticles for targeted therapeutic delivery. Bioeng. Transl. Med.2(1), 43–57 (2017).
   PubMed Web of Science ®Google Scholar
• Kato T , TakamiY, KumarDV, ParkEY. Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells. J. Biotechnol.306, 177–184 (2019).
   PubMed Web of Science ®Google Scholar
• Wang C , ZhengX, GaiWet al. Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice. Antiviral Res.140, 55–61 (2017).
   PubMed Web of Science ®Google Scholar
• Kim Y-S , SonA, KimJet al. Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles. Front. Immunol.9(1093), 1–20 (2018).
   PubMedGoogle Scholar
• Fang N , FrazerIH, FernandoGJP. Differences in the post-translational modifications of human papillomavirus type 6b major capsid protein expressed from a baculovirus system compared with a vaccinia virus system. Biotechnol. Appl. Biochem.32(1), 27–33 (2000).
   PubMedGoogle Scholar
• Todd TJ , ZhenZ, XieJ. Ferritin nanocages: great potential as clinically translatable drug delivery vehicles?Nanomedicine (Lond.)8(10), 1555–1557 (2013).
   PubMed Web of Science ®Google Scholar
• Clark EDB . Refolding of recombinant proteins. Curr. Opin. Biotechnol.9(2), 157–163 (1998).
   PubMed Web of Science ®Google Scholar
• Pimentel TaPF , YanZ, JeffersSA, HolmesKV, HodgesRS, BurkhardP. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem. Biol. Drug Des.73(1), 53–61 (2009).
   PubMed Web of Science ®Google Scholar
• Chen HW , HuangCY, LinSYet al. Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an avian model of coronavirus infection. Biomaterials106, 111–118 (2016).
   PubMed Web of Science ®Google Scholar
• Dykman LA , KhlebtsovNG. Immunological properties of gold nanoparticles. Chem. Sci.8(3), 1719–1735 (2017).
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A , BasuS, SinghaS, PatraHK. Inner-view of nanomaterial incited protein conformational changes: insights into designable interaction. Research2018, 1–15 (2018).
   Google Scholar
• Wang C , HorbyPW, HaydenFG, GaoGF. A novel coronavirus outbreak of global health concern. Lancet395(10223), 470–473 (2020).
   PubMed Web of Science ®Google Scholar
• Zhao Z , CuiH, SongW, RuX, ZhouW, YuX. A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2. bioRxiv doi: 10.1101/2020.02.22.961268 (2020) ( Preprint).
   Google Scholar
• Gong P , HeX, WangK, TanWet al. Combination of functionalized nanoparticles and polymerase chain reaction-based method for SARS-CoV gene detection. J. Nanosci. Nanotechnol.8(1), 293–300 (2008).
   PubMed Web of Science ®Google Scholar
• Radwan SH , AzzazyHM. Gold nanoparticles for molecular diagnostics. Exp. Rev. Mol. Diagnost.9(5), 511–524 (2009).
   PubMed Web of Science ®Google Scholar
• Laromaine A , KohL, MurugesanM, UlijnRV, StevensMM. Protease-triggered dispersion of nanoparticle assemblies. J. Am. Chem. Soc.129(14), 4156–4157 (2007).
   PubMed Web of Science ®Google Scholar
• Kim H , ParkM, HwangJet al. Development of label-free colorimetric assay for MERS-CoV using gold nanoparticles. ACS Sensors4(5), 1306–1312 (2019).
   PubMed Web of Science ®Google Scholar
• Li H , RothbergL. Colorimetric detection of DNA sequences based on electrostatic interactions with unmodified gold nanoparticles. Proc. Natl Acad. Sci. USA101(39), 14036–14039 (2004).
   PubMed Web of Science ®Google Scholar
• Martínez-Paredes G , González-GarcíaMB, Costa-GarcíaA. Genosensor for SARS virus detection based on gold nanostructured screen-printed carbon electrodes. Electroanalysis21(3–5), 379–385 (2009).
   Web of Science ®Google Scholar
• Ahmed SR , NagyÉ, NeethirajanS. Self-assembled star-shaped chiroplasmonic gold nanoparticles for an ultrasensitive chiro-immunosensor for viruses. RSC Adv.7(65), 40849–40857 (2017).
   Web of Science ®Google Scholar
• AssayGenie . Rapid COVID-19 antibody detection tests: principles and methods. http://www.assaygenie.com/rapid-covid19-antibody-detection-tests-principles-and-methods
   Google Scholar
• Xiang J , YanM, LiHet al. Evaluation of enzyme-linked immunoassay and colloidal gold-immunochromatographic assay kit for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia (COVID-19). medRxiv doi: 10.1101/2020.02.27.20028787 (2020) ( Preprint).
   Google Scholar
• Huang P , WangH, CaoZet al. A rapid and specific assay for the detection of MERS-CoV. Front. Microbiol.9(1101), 1–9 (2018).
   PubMedGoogle Scholar
• Huang X , LiM, XuYet al. Novel gold nanorod-based HR1 peptide inhibitor for Middle East respiratory syndrome coronavirus. ACS Appl. Mater. Interfaces11(22), 19799–19807 (2019).
   PubMed Web of Science ®Google Scholar
• Han Y , KrálP. Computational design of ACE2-based peptide inhibitors of SARS-CoV-2. ACS Nano14(4), 5143–5147 (2020).
   PubMed Web of Science ®Google Scholar
• Duffy S . Why are RNA virus mutation rates so damn high?PLoS Biol.16(8), e3000003 (2018).
   PubMed Web of Science ®Google Scholar
• Foudeh AM , FatanatDidar T, VeresT, TabrizianM. Microfluidic designs and techniques using lab-on-a-chip devices for pathogen detection for point-of-care diagnostics. Lab Chip12(18), 3249–3266 (2012).
   PubMed Web of Science ®Google Scholar